Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 51% primary Improvement Relative Risk Case 27% c19hcq.org Polo et al. NCT04334928 EPICOS HCQ RCT PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Double-blind RCT 435 patients in Spain Fewer cases with HCQ (not stat. sig., p=0.31) Polo et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006 Favors HCQ Favors control
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers
Polo et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006, EPICOS, NCT04334928 (history)
Polo et al., Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of.., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006, EPICOS, NCT04334928
Aug 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Early terminated healthcare worker prophylaxis RCT in Spain, showing lower risk of symptomatic cases with HCQ prophylaxis, without statistical significance due to the small number of events.
risk of symptomatic case, 51.0% lower, RR 0.49, p = 0.79, treatment 3 of 224 (1.3%), control 5 of 211 (2.4%), NNT 97, Kaplan–Meier, primary outcome.
risk of case, 27.0% lower, RR 0.73, p = 0.31, treatment 21 of 224 (9.4%), control 23 of 211 (10.9%), Kaplan–Meier.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Polo et al., 5 Aug 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, median age 38.0, 189 authors, trial NCT04334928 (history) (EPICOS).
Contact: jamo@sanidad.gob.es.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for preexposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers R. Polo, X. García-Albéniz, C. Terán, M. Morales, D. Rial-Crestelo, M.A. Garcinuño, M. García del Toro, C. Hita, J.L. Gómez-Sirvent, L. Buzón, A. Díaz de Santiago, J.L. Pérez Arellano, J. Sanz, P. Bachiller, E. Martínez Alfaro, V. Díaz-Brito, M. Masiá, A. Hernández-Torres, J. Guerra, J. Santos, P. Arazo, L. Muñoz, J.R. Arribas, P. Martínez de Salazar, S. Moreno, M.A. Hernán, J. Del Amo, on behalf of EPICOS, EPICOS investigator team, Julia del Amo, Principal Investigator, Rosa Polo, Principal Investigator, Santiago Moreno, Principal Investigator, Juan Berenguer, Principal Investigator, Esteban Martínez, Principal Investigator, Miguel Hernán, Principal Investigator, Pablo Martínez de Salazar, Principal Investigator, Xabier García de Albéniz, Principal Investigator, Collaborators, Data safety monitoring board, Contract Research Organization, Participating hospitals PII: S1198-743X(22)00370-6 DOI: https://doi.org/10.1016/j.cmi.2022.07.006 Reference: CMI 3013 To appear in: Clinical Microbiology and Infection Received Date: 7 February 2022 Revised Date: 6 July 2022 Accepted Date: 9 July 2022 Please cite this article as: Polo R, García-Albéniz X, Terán C, Morales M, Rial-Crestelo D, Garcinuño M, García del Toro M, Hita C, Gómez-Sirvent J, Buzón L, Díaz de Santiago A, Pérez Arellano J, Sanz J, Bachiller P, Martínez Alfaro E, Díaz-Brito V, Masiá M, Hernández-Torres A, Guerra J, Santos J, Arazo P, Muñoz L, Arribas J, Martínez de Salazar P, Moreno S, Hernán M, Del Amo J, on behalf of EPICOS, on behalf of EPICOS investigator team, EPICOS investigator team, del Amo J, Rosa Polo Moreno S, Berenguer J, Martínez E, Hernán M, Martínez de Salazar P, García de Albéniz X, Collaborators, Data safety monitoring board, Contract Research Organization, Participating hospitals, Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2022.07.006. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers Polo R1, García-Albéniz X2,3, Terán C4, Morales M5, Rial-Crestelo D6,7, Garcinuño oo f MA8, García del Toro M9, Hita C10, Gómez-Sirvent JL11, Buzón L12, Díaz de Santiago re -p r A13, Pérez Arellano JL14, Sanz J7,15, Bachiller P16, Martínez Alfaro E17, Díaz-Brito V18, Masiá M7,19, Hernández-Torres A20, Guerra J21, Santos J22, Arazo P23,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit